Navigation Links
New discovery paves the way for new diagnosis of serious lung disease
Date:3/2/2009

The discovery by Uppsala University researchers of a previously unknown protein in the cells of the lower air ways brings new potential for early diagnosis of a serious lung disease. The findings, published today in the Web edition of the American journal Proceedings of the National Academy of Sciences, can also provide new knowledge of the cause of common diseases like asthma and chronic bronchitis.

Researchers at Uppsala University and Uppsala University Hospital have identified a protein in the lungs that is important to the immune defense system in an autoimmune lung disorder that is not seldom fatal. The newly discovered protein, called KCNRG, occurs in cells in the lower air ways found on the surface of the bronchia. This observation enables researchers to study more closely the first phase of the autoimmune disease, that is, when the immune system erroneously attacks the body's own tissues instead of attacking foreign organisms like bacteria or viruses. The discovery also provides new avenues for developing new diagnostic methods.

The researchers used an unusual hereditary autoimmune disorder, autoimmune polyendocrine syndrome type 1 (APS-1), as a model. Patients with this disease are afflicted by the immune system erroneously attacking several tissues, such as the liver, insulin-producing cells, and adrenal glands.

"Only now have we understood that the lungs are attacked as well and that in many cases this is the most serious component of the disease APS-1," says Dr. Mohammad Alimohammadi.

"It's our hope that the discovery of the protein that the immune system targets, besides making early diagnosis possible, will also be possible to use in understanding the mechanism behind the occurrence of common public health disorders like asthma and chronic bronchitis."


'/>"/>

Contact: Mohammad Alimohammadi
mohammad.alimohammadi@medsci.uu.se
46-070-882-9922
Uppsala University
Source:Eurekalert

Page: 1

Related biology news :

1. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
2. Rett Syndrome Research Trust advisor makes significant discovery
3. Singapore research organisations team up to advance drug discovery using brain tumor stem cells
4. Breaking the barrier: Discovery of anti-resistance factors and novel ocean drugs
5. Major step for drug discovery and diagnostics
6. Cell-building discovery could reduce need for some animal research
7. New discovery may lead to new class of allergy drugs
8. Discovery could lead to a new animal model for hepatitis C
9. Billion-year revision of plant evolution timeline may stem from discovery of lignin in seaweed
10. Cancer-causing gene discovery suggests new therapies
11. Jumbo-sized discovery made in Malaysia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology: